BioLineRx (NASDAQ:BLRX – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $21.00 target price on the biotechnology company’s stock.
Separately, StockNews.com assumed coverage on shares of BioLineRx in a research note on Thursday, October 5th. They issued a “sell” rating for the company.
BioLineRx Stock Performance
BioLineRx (NASDAQ:BLRX – Get Free Report) last issued its earnings results on Wednesday, August 30th. The biotechnology company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($0.14). During the same quarter in the previous year, the company posted ($0.16) earnings per share. As a group, sell-side analysts anticipate that BioLineRx will post -0.83 EPS for the current fiscal year.
Hedge Funds Weigh In On BioLineRx
A number of large investors have recently made changes to their positions in BLRX. LPL Financial LLC boosted its stake in BioLineRx by 6.4% in the 2nd quarter. LPL Financial LLC now owns 125,210 shares of the biotechnology company’s stock worth $200,000 after purchasing an additional 7,500 shares during the period. Geneos Wealth Management Inc. increased its holdings in BioLineRx by 72.3% during the 3rd quarter. Geneos Wealth Management Inc. now owns 40,500 shares of the biotechnology company’s stock worth $74,000 after acquiring an additional 17,000 shares during the period. Renaissance Technologies LLC lifted its stake in BioLineRx by 49.1% in the 3rd quarter. Renaissance Technologies LLC now owns 68,222 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 22,478 shares in the last quarter. Rathbones Group PLC bought a new position in BioLineRx in the 3rd quarter valued at $72,000. Finally, Values First Advisors Inc. purchased a new position in shares of BioLineRx during the 3rd quarter valued at $88,000. 2.01% of the stock is owned by institutional investors.
BioLineRx Company Profile
BioLineRx Ltd., a pre-commercial-stage biopharmaceutical company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia.
- Five stocks we like better than BioLineRx
- 3 Monster Growth Stocks to Buy Now
- The most upgraded stocks in November have two things in common
- What is an Earnings Surprise?
- Monday.com rocked earnings like it’s the weekend
- How to Choose Top Rated Stocks
- Plan to own one retailer? Make it this one
Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter.